
Releases
FDA Grants Orphan Drug Status to Potential MAOD Treatment
The U.S. Food and Drug Administration has granted Orphan Drug Designation to para-cloro-phenylalanine, a potential therapy for monoamine oxidase deficiency. This regulatory milestone offers a new pathway for addressing the rare neurodevelopmental disorder, which has long been characterized by a lack of clinical guidance and viable treatment options.

























